a b s t r a c t
In this article, a new concept of an "endophenotype-associated surrogate endpoint (EASE)" is proposed.
To examine effect of a novel therapeutic molecule on a target phenotype of a genotype associated with the molecule, state-dependent aspect of an endophenotype can be used as a surrogate endpoint. Desired characteristics for EASE are (1) a close relationship to the endophenotype associated with therapeutics, (2) longitudinal changes in illness severity, while the original "endophenotype" is primarily state independent, (3) a physical sign or laboratory measurement that occurs in association with a pathological process and has putative diagnostic and/or prognostic utility, and (4) serves as a substitute for a clinically meaningful endpoint. Advantages are expected for both surrogate endpoints in drug development and endophenotypes in uncovering pathogenesis. EASE are closer to molecules than clinically meaningful endpoints and can respond to administration of the molecule in a more direct manner. Therefore, a statistically significant effect is likely to be observed in clinical trials with smaller sample sizes and shorter durations. As with endophenotypes, reduced heterogeneity might be expected especially in heterogeneous syndromes such as psychiatric disorders. Potential interactions (e.g., elucidating biological mechanisms underlying novel treatments) can be further expected.
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Introduction
Highly prevalent and currently untreatable disease symptoms, such as negative symptoms in schizophrenia or sociocommunicational deficits in autism spectrum disorder (ASD), are considered to be huge unmet medical needs that lead to a heavy burden on people with the disorders, their families, and society as a whole. Clinical research should essentially be aimed at satisfying these unmet needs, regardless of using a direct or indirect approach. However, although research in this field is increasing, the research findings accumulating do not necessarily contribute to satisfying these unmet needs.
The multifactorial and polygenic genetic origin of psychiatric disorders complicates attempts to uncover the neurobiological mechanisms and develop novel effective treatments for the * Correspondence to: Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. Tel.: +81 3 3815 5411; fax: +81 3 5800 6894.
E-mail address: yamasue-tky@umin.ac.jp symptoms. These disorders, clinically defined as syndromes based on phenotypes at the behavioral level, are biologically heterogeneous. To resolve this issue, endophenotypes are used in clinical research with expectation reducing heterogeneity in these clinically defined syndromes, although the notion has recently been criticized (Flint et al., 2014). The term "endophenotype" was provided by John and Lewis in 1966, and further developed in psychiatry by Gottesman and Shields in 1973. Endophenotypes were originally defined as measurable components unseen by the unaided eye along the pathway between disease and distal genotype. Gottesman and Gould (2003) stated that "Endophenotypes for psychiatric disorders must meet certain criteria, including association with a candidate gene or gene region, heritability that is inferred from relative risk for the disorder in relatives, and disease association parameters." Their criteria for an endophenotype were:
